As of 10:02am ET
| +0.18 / +2.90%|
The 3 analysts offering 12-month price forecasts for Trinity Biotech PLC have a median target of 9.00, with a high estimate of 12.00 and a low estimate of 8.50. The median estimate represents a +40.85% increase from the last price of 6.39.
The current consensus among 4 polled investment analysts is to Buy stock in Trinity Biotech PLC. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.